Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 8/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.76 |
| ▸ | TBXAS1 | P24557 | 11/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | PTGIS | Q16647 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13378991 | 1.00 | TBXA2R (0.76) | TBXA2RCYP1A2CYP3A4MEN1CYP2D6 | |
| SCHEMBL1897185 | 0.91 | TBXA2R (0.79) | TBXA2RCYP1A2CYP3A4MEN1CYP2D6 | |
| SCHEMBL13378988 | 0.91 | TBXA2R (0.79) | TBXA2RCYP1A2CYP3A4MEN1CYP2D6 | |
| SCHEMBL12675359 | 0.91 | TBXA2R (0.79) | TBXA2RCYP1A2CYP3A4MEN1CYP2D6 | |
| SCHEMBL15301375 | 0.91 | TBXA2R (0.79) | TBXA2RCYP1A2CYP3A4MEN1CYP2D6 | |
| SCHEMBL3092746 | 0.91 | TBXA2R (0.79) | TBXA2RCYP1A2CYP3A4MEN1CYP2D6 | |
| SCHEMBL13378990 | 0.89 | TBXA2R (0.61) | TBXA2RCYP1A2CYP3A4MEN1CYP2D6 | |
| SCHEMBL12675699 | 0.89 | TBXA2R (0.61) | TBXA2RCYP1A2CYP3A4MEN1CYP2D6 | |
| SCHEMBL12675693 | 0.89 | TBXA2R (0.76) | TBXA2RCYP1A2CYP3A4MEN1CYP2D6 | |
| SCHEMBL13379002 | 0.89 | TBXA2R (0.76) | TBXA2RCYP1A2CYP3A4MEN1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160193179-A1 | Treatment of Cardiovascular Risk in Diabetic Patients | SAKARIASSEN KJELL STEINAR (IT) | 2016-07-07 | — | — | US | disclosed |
| US-20160193179-A1 | Treatment of Cardiovascular Risk in Diabetic Patients | SAKARIASSEN KJELL STEINAR (IT) | 2016-07-07 | — | — | US | disclosed |
| WO-2015193630-A1 | TREATMENT OF CARDIOVASCULAR RISK IN PATIENTS WITH CARDIOVASCULAR DISEASE AND/OR DIABETES | EVOLVA SA (CH) | 2015-12-23 | — | — | WO | disclosed |
| WO-2014106775-A2 | TREATMENT OF CARDIOVASCULAR RISK IN DIABETIC PATIENTS | EVOLVA SA (CH) | 2014-07-10 | — | — | WO | disclosed |
| WO-2011057262-A2 | TREATMENT OF INFECTIONS WITH TP RECEPTOR ANTAGONISTS | EVOLVA INC. (US) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160193179-A1 | Treatment of Cardiovascular Risk in Diabetic Patients | P2RY12, P2RY13, P2RY6 | TBXA2R 19/4885CYP1A2 1425/4885CYP3A4 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.